NasdaqGS:XERS

Stock Analysis Report

Executive Summary

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.

Rewards

Trading at 96.9% below its fair value

Revenue is forecast to grow 46.98% per year

Revenue grew by 12.3% over the past year

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 2 more risks


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Xeris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XERS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-17.3%

XERS

5.9%

US Pharmaceuticals

-2.8%

US Market


1 Year Return

-82.5%

XERS

-6.3%

US Pharmaceuticals

-15.9%

US Market

Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned -6.3% over the past year.

Return vs Market: XERS underperformed the US Market which returned -15.9% over the past year.


Shareholder returns

XERSIndustryMarket
7 Day-17.3%5.9%-2.8%
30 Day-35.8%-7.7%-18.8%
90 Day-70.7%-11.3%-24.0%
1 Year-82.5%-82.5%-3.9%-6.3%-14.2%-15.9%
3 Yearn/a13.7%5.5%9.9%2.8%
5 Yearn/a13.8%1.3%27.2%13.3%

Price Volatility Vs. Market

How volatile is Xeris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xeris Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XERS ($1.7) is trading below our estimate of fair value ($55.46)

Significantly Below Fair Value: XERS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XERS is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: XERS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XERS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XERS is overvalued based on its PB Ratio (3.2x) compared to the US Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Xeris Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

52.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XERS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XERS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XERS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XERS's revenue (47% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: XERS's revenue (47% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XERS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xeris Pharmaceuticals performed over the past 5 years?

-109.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: XERS is currently unprofitable.

Growing Profit Margin: XERS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if XERS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare XERS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XERS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).


Return on Equity

High ROE: XERS has a negative Return on Equity (-869.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is Xeris Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: XERS's short term assets ($87.5M) exceed its short term liabilities ($27.3M).

Long Term Liabilities: XERS's short term assets ($87.5M) exceed its long term liabilities ($67.2M).


Debt to Equity History and Analysis

Debt Level: XERS's debt to equity ratio (403.9%) is considered high.

Reducing Debt: Insufficient data to determine if XERS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: XERS has a low level of unsold assets or inventory.

Debt Coverage by Assets: XERS's debt is covered by short term assets (assets are 1.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XERS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XERS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -56.9% each year


Next Steps

Dividend

What is Xeris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XERS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XERS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XERS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XERS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XERS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Paul Edick (63yo)

3.25s

Tenure

US$1,314,251

Compensation

Mr. Paul R. Edick has been the Chief Executive Officer, President and Director of Xeris Pharmaceuticals, Inc. since January 10, 2017 and has been its Chairman since June 2018. He was Chairman of the Board  ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD1.31M) is above average for companies of similar size in the US market ($USD626.05K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Edick
President3.25yrsUS$1.31m0.27% $174.3k
Barry Deutsch
Chief Financial Officer2yrsUS$948.18k0.10% $66.7k
John Shannon
Executive VP & COO3.17yrsUS$918.49k0.060% $38.3k
Steven Prestrelski
Co-Founder & Chief Scientific Officerno datano data1.12% $715.0k
Allison Wey
Senior Vice President of Investor Relations & Corporate Communications1.75yrsno datano data
Beth Hecht
Senior VPno datano data0.032% $20.5k
Kenneth Johnson
Senior Vice President of Clinical Developmentno datano data0.016% $10.4k
Kevin McCulloch
Senior Vice President of Global Operations & Business Developmentno datano datano data

2.6yrs

Average Tenure

55.5yo

Average Age

Experienced Management: XERS's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Paul Edick
President3.25yrsUS$1.31m0.27% $174.3k
John Brooks
Scientific Advisory Board Memberno datano datano data
Orville Kolterman
Member of Scientific Advisory Boardno datano datano data
Jeffrey Sherman
Independent Non-Executive Board Member2yrsUS$164.76kno data
John Schmid
Independent Non-Executive Board Member2.58yrsUS$224.75k0.015% $9.6k
W. Ward
Member of Scientific Advisory Boardno datano datano data
Marla Persky
Independent Non-Executive Board Member2yrsUS$169.26kno data
Morey Haymond
Scientific Advisory Board Memberno datano datano data
Barbar-Jean Bormann-Kennedy
Independent Non-Executive Board Member2yrsUS$172.26kno data
Dawn Halkuff
Independent Non-Executive Board Member2yrsUS$167.76kno data

2.0yrs

Average Tenure

63yo

Average Age

Experienced Board: XERS's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XERS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 116.8%.


Top Shareholders

Company Information

Xeris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xeris Pharmaceuticals, Inc.
  • Ticker: XERS
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$63.681m
  • Shares outstanding: 37.57m
  • Website: https://www.xerispharma.com

Number of Employees


Location

  • Xeris Pharmaceuticals, Inc.
  • 180 North LaSalle Street
  • Suite 1810
  • Chicago
  • Illinois
  • 60601
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XERSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
2B3DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/05 07:33
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.